Pacific Biosciences of California, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Pacific Biosciences of California, Inc. has filed its 2026 Proxy Statement, outlining proposals for the upcoming Annual Meeting, including director elections, executive compensation, and an amendment to the 2020 Equity Incentive Plan.
NASDAQ
Pacific Biosciences has filed a definitive proxy statement with the SEC.
NASDAQ
Pacific Biosciences has filed a definitive proxy statement with the SEC.
NASDAQ
Pacific Biosciences is asking stockholders to approve an amendment to its 2020 Equity Incentive Plan to increase the number of shares reserved for issuance.
NASDAQ
Pacific Biosciences of California, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Pacific Biosciences of California, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Pacific Biosciences is asking stockholders to vote on proposals to declassify the board of directors and limit officer liability at the upcoming annual meeting.